Survival Outcomes and Sensitivity of PARP Inhibitors in Platinum‐Sensitive Ovarian Cancer: A Retrospective Study

Key Points

• This research aims to evaluate survival outcomes and identify sensitivity markers for PARP inhibitors in ovarian cancer patients.
• Conducted a retrospective analysis of Chinese ovarian cancer patients receiving PARP inhibitor maintenance therapy.
• Identified biomarkers TFRC and PRNP for predicting PARPi sensitivity.
• Over 20% of patients exhibited primary resistance to PARP inhibitors.
• TFRC and PRNP are potential biomarkers for assessing PARPi sensitivity, requiring further validation.